乳腺癌ER、PR、C-erbB-2表达与新辅助化疗有效率的关系  

Relationship between Expressions of ER,PR,C-erbB-2 and Response rates of Neoadjuvant Chemotherapy in Breast Cancer

作　　者：肖天林[1] 龚志敏[1] 杨超[1] 

机构地区：[1]湖北省襄樊市中心医院肿瘤科,襄樊441021

出　　处：《中国医药导刊》2011年第2期239-240,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:探讨乳腺癌患者术前ER、PR、C-erbB-2的表达与新辅助化疗(NCT)有效率的关系。方法:采用免疫组化方法,检测180例乳腺癌NCT患者化疗前ER、PR、C-erbB-2的表达情况,观察不同表达情况下NCT的疗效。结果:180例乳腺癌NCT病例中,ER、PR、C-erbB-2阴性率分别为32.2%、23.3%、40.0%,ER(+)组与ER(-)组、PR(+)组与PR(-)组化疗有效率差异均有统计学意义(P<0.05),C-erbB-2高表达组与低表达组化疗有效率差异有统计学意义(P<0.05)。结论:ER、PR阴性及C-erbB-2低表达的乳腺癌病人对化疗更敏感,化疗后获益更多,ER、PR阴性表达及C-erbB-2低表达可作为乳腺癌NCT敏感性的预测指标。Objective： To observe the relationship between clinical efficacy of neoadjuvant chemotherapy on breast cancer and the expression of ER,PR and C-erbB-2 before surgery. Methods：One hundred and eighty cases with breast cancer were examined different expression of ER, PR and C-erbB-2 immunohistochemically before the surgery, and the response rates, the pathological relief rates were compared between different expression groups. Results：The negative expression of ER, PR and C-erbB-2 of 180 patients were respectively 32.2%,23.3%,40.0%,and the response rates drew a statistically difference between positive and negative of ER,PR groups, high and low expression group of C-erbB-2（P〈0.05）. Conclusions： In the patients with breast cancer, the negative expression of ER, PR and low expression of C-erbB-2 are more sensitive to chemotherapy. These patients may get more benefits from chemotherapy.The negative expression of ER,PR and low expression of C-erbB-2 can be considered as predictive markers of the effective rate of neoadjuvant chemotherapy.

关 键 词：乳腺癌 新辅助化疗 ER、PR、C-erbB-2表达 

分 类 号：R737.9[医药卫生—肿瘤]